Renin-angiotensin system blockers and mortality in COVID-19: a territory-wide study from Hong Kong

Jiandong Zhou MSc #¹, Gary Tse PhD FRCP FFPH #², Sharen Lee³, Wing Tak Wong PhD⁴, Xingsong Wang MSc⁵, William KK Wu PhD FRCPath FRCP⁵, Tong Liu MD PhD¹, Zhidong Cao PhD⁶, Daniel Dajun Zeng PhD⁶, Ian Chi Kei Wong PhD⁷, Bernard Man Yung Cheung MB BChir PhD FRCP⁸, Qingpeng Zhang PhD¹

¹ School of Data Science, City University of Hong Kong, Hong Kong, Hong Kong, China

² Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China

³ Laboratory of Cardiovascular Physiology, Li Ka Shing Institute of Health Sciences, China

⁴ School of Life Sciences, The Chinese University of Hong Kong, Hong Kong, China

⁵ Department of Anaesthesia and Intensive Care, Li Ka Shing Institute of Health Sciences, Hong Kong, China

⁶ Institute of Automation, Chinese Academy of Sciences, Beijing, China.

⁷ Department of Pharmacology and Pharmacy, University of Hong Kong, Pokfulam, Hong Kong, China

⁸ Division of Clinical Pharmacology and Therapeutics, Department of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China

joint first authors

* Correspondence to:

Dr. Gary Tse PhD FRCP, FFPH

Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China

Email: garytse86@gmail.com

Prof. Bernard Man Yung Cheung MB BChir PhD FRCP

Department of Medicine, The University of Hong Kong, Room 405B, 4/F, Professorial Block, Queen Mary Hospital, 102 Pok Fu Lam Road, Pok Fu Lam,

Hong Kong, China

Email: mycheung@hku.hk

Tel: +852 22554347

Dr. Qingpeng Zhang PhD

School of Data Science, City University of Hong Kong,

Hong Kong SAR, China

Email: qingpeng.zhang@cityu.edu.hk

+852 34424727

Key Points:

- We report that an association between ACEIs/ARBs with COVID-19 related mortality even after adjusting for cardiovascular and other comorbidities, as well as medication use.
- Patients with greater comorbidity burden and laboratory markers reflecting deranged clotting, renal and liver function, and increased tissue inflammation, and ACEI/ARB use have a higher mortality risk.

Key words: ACE inhibitors; angiotensin receptor blockers; COVID-19; mortality

Acknowledgements: None

Conflicts of Interest: None

Abstract

Aims: Renin–angiotensin system blockers such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may increase the risk of adverse outcomes in COVID-19. In this study, the relationships between ACEI/ARB use and COVID-19 related mortality were examined.

Methods: Consecutive patients diagnosed with COVID-19 by RT-PCR at the Hong Kong Hospital Authority between 1st January and 28th July 2020 were included.

Results: This study included 2774 patients. The mortality rate of the COVID-19 positive group was 1.5% (n=42). Those who died had a higher median age (82.3[76.5-89.5] vs. 42.9[28.2-59.5] years old; $P<0.0001$), more likely to have baseline comorbidities of cardiovascular disease, diabetes mellitus, hypertension, and chronic kidney disease ($P<0.0001$). They were more frequently prescribed ACEI/ARBs at baseline, and steroids, lopinavir/ritonavir, ribavirin and hydroxychloroquine during admission ($P<0.0001$). They also had a higher white cell count, higher neutrophil count, lower platelet count, prolonged prothrombin time and activated partial thromboplastin time, higher D-dimer, troponin, lactate dehydrogenase, creatinine, alanine transaminase, aspartate transaminase and alkaline phosphatase ($P<0.0001$). Multivariate Cox regression showed that age, cardiovascular disease, renal disease, diabetes mellitus, the use of ACEIs/ARBs and diuretics, and various laboratory tests remained significant predictors of mortality.

Conclusions: We report that an association between ACEIs/ARBs with COVID-19 related mortality even after adjusting for cardiovascular and other comorbidities, as well as medication use. Patients

with greater comorbidity burden and laboratory markers reflecting deranged clotting, renal and liver function, and increased tissue inflammation, and ACEI/ARB use have a higher mortality risk.

Introduction

The use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) has been associated with poor disease outcomes in coronavirus disease 2019 (COVID-19). For example, a population-based cohort study from Korea found that ACE-I or ARB therapy in patients with severe COVID-19 was associated with the occurrence of severe complications and increased in-hospital mortality [1]. By contrast, other studies did not identify an increased risk of severe COVID-19 [2, 3] or mortality [4] among patients taking ACEIs or ARBs. A systematic review and meta-analysis of 33 studies found that ACE inhibitor use was marker of increased mortality risk in some, but not all, COVID-19 disease settings [5], whilst another found that The risk of mortality and severe outcomes are also unchanged among COVID-19 patients taking ACEI/ARB [6]. Nevertheless, prior use of RAAS inhibitors was associated with lower risk mortality from COVID-19 specifically in patients with hypertension [7]. Given these conflicting findings, we examined whether the use of ACEIs/ARBs is related to COVID-19 mortality using territory-wide data from Hong Kong.

Methods

Study design and population

This study was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster. This was a retrospective, territory-wide cohort study of patients undergoing COVID-19 RT-PCR testing between 1st January and 28th July 2020. The patients were identified from the Clinical Data Analysis and Reporting System (CDARS), a territory-wide database that centralizes patient information from individual local hospitals to establish comprehensive medical data, including clinical characteristics, disease diagnosis, laboratory results, and drug treatment details. The system has been previously used by both our team and other teams in Hong Kong [8-11]. The list of conditions identified is detailed in the **Supplementary Appendix**. Patients and the public were not engaged in this study.

Outcomes and statistical analysis

All-cause mortality was the primary outcome for the COVID-19 positive group, with last date of mortality status on 8th August 2020. Continuous variables were presented as median (95% confidence interval [CI] or interquartile range[IQR]) and categorical variables were presented as count (%). The Mann-Whitney U test was used to compare continuous variables. The χ^2 test with Yates' correction was used for 2×2 contingency data. Statistical analyses were performed using RStudio software (Version: 1.1.456) and Python (Version: 3.6).

Results

A total of 2774 patients with confirmed COVID-19 were included. Their baseline characteristics are shown in **Table 1**. A total of 42 deaths occurred (1.5%) in the 2774 patients who were diagnosed with COVID-19. Those who died had a higher median age (82.3[76.5-89.5] vs. 42.9[28.2-59.5] years old), more likely to have baseline comorbidities of cardiovascular disease, diabetes mellitus, hypertension, and chronic kidney disease. Moreover, they were more frequently prescribed ACEI/ARBs at baseline, and steroids, lopinavir/ritonavir, ribavirin and hydroxychloroquine during admission. Finally, patients who died had a higher white cell count, higher neutrophil count, lower platelet count, prolonged PT and activated partial thromboplastin time, higher D-dimer, troponin and lactate dehydrogenase. Moreover, creatinine, alanine transaminase, aspartate transaminase and alkaline phosphatase were significantly higher for the mortality group.

Univariate Cox regression was used to identify predictors of mortality in patients who were positive for COVID-19 (**Table 2**). This identified age, baseline cardiovascular and renal diseases, diabetes, hypertension, the use of ACEIs/ARBs, other anti-hypertensive agents, and anti-viral drugs in COVID-19, as well as various haematology and biochemical tests. On multivariate analysis, age, cardiovascular disease, renal disease, diabetes mellitus, the use of ACEIs/ARBs and diuretics, and various laboratory tests remained significant predictors of mortality (**Table 3**).

Discussion

The main findings of this territory-wide cohort study are that 1) a higher proportion of ACEI/ARB prescription was observed for the COVID-19 positive compared to COVID-19 negative

group and 2) those who died had a higher median age and more likely to have baseline comorbidities of cardiovascular disease, diabetes mellitus, hypertension, and chronic kidney disease and 3) ACEI/ARB use was significantly associated with mortality even after adjusting for cardiovascular comorbidities and the use of other anti-hypertensive agents. Moreover, they were more frequently prescribed ACEI/ARBs at baseline, and steroids, lopinavir/ritonavir, ribavirin and hydroxychloroquine during admission.

The relationship between ACEI/ARB use and disease outcomes in COVID-19 has been investigated. Many of the previous studies have included hospitalized patients only. For example, in a multi-centre study from China, it was found that in hospitalized patients with COVID-19 and existing hypertension, ACEI/ARB inpatient users had a lower risk of all-cause mortality compared with nonusers [12]. In our study, we found that in those who died, there was a higher frequency of patients with ACE inhibitor/ARB use compared to those who remained alive. However, on multivariate Cox regression, ACEI/ARB use retained its significance for mortality prediction even after multivariate adjustment for cardiovascular comorbidities and the use of other anti-hypertensive agents. Nevertheless, the frequency of hypertension, diabetes mellitus and cardiovascular disease were also higher in the mortality group. This is in keeping with previous demonstrations that patients with pre-existing cardio-metabolic comorbidities are at higher risk of severe disease or mortality [13].

In terms of laboratory findings, prior studies have demonstrated the presence of organ damage in COVID-19. Indeed, there have been reported associations between elevations in myocardial biomarkers and mortality [14-16]. Alterations in other laboratory markers that have been associated

with adverse outcomes in COVID-19 include increases in D-dimer levels [17], liver enzymes [18], neutrophil count [19], activated partial thromboplastin time and prothrombin time [20]. In our study, we also found that patients who died had a higher white cell count, higher neutrophil count, lower platelet count, prolonged prothrombin time and activated partial thromboplastin time, D-dimer, troponin, lactate dehydrogenase, creatinine, alanine transaminase, aspartate transaminase and alkaline phosphatase.

Conclusion

Taken together, we report that an association between ACEIs or ARBs with COVID-19 related mortality even after adjusting for cardiovascular and other comorbidities, as well as medication use. Our findings suggest that patients with greater comorbidity burden and laboratory markers reflecting deranged clotting, renal and liver function, and increased tissue inflammation, as well as ACEI/ARB use have a higher mortality risk.

Conflicts of Interest

None.

Funding

None.

Contributorship Statement

GT: study conception, study design, data acquisition, statistical analysis, data interpretation, manuscript drafting, critical revision of manuscript

JZ: statistical analysis, data interpretation, manuscript drafting, critical revision of manuscript

SL, WTW, XW, WKKW, TL, ZC, DZ, KCKW: data interpretation, critical revision of manuscript

BMYC, QZ: project administration and supervision, statistical analysis, data interpretation, critical revision of manuscript

Guarantor of overall content: GT

References

1. Lim JH, Cho JH, Jeon Y, Kim JH, Lee GY, Jeon S, et al. Adverse impact of renin-angiotensin system blockade on the clinical course in hospitalized patients with severe COVID-19: a retrospective cohort study. *Sci Rep*. 2020 Nov 20;10(1):20250.
2. Bauer AZ, Gore R, Sama SR, Rosiello R, Garber L, Sundaresan D, et al. Hypertension, medications, and risk of severe COVID-19: A Massachusetts community-based observational study. *J Clin Hypertens (Greenwich)*. 2020 Nov 21.
3. Martinez-Del Rio J, Piqueras-Flores J, Nieto-Sandoval Martin de la Sierra P, Negreira-Caamano M, Aguila-Gordo D, Mateo-Gomez C, et al. Comparative analysis between the use of renin-angiotensin system antagonists and clinical outcomes of hospitalized patients with COVID-19 respiratory infection. *Med Clin (Engl Ed)*. 2020 Nov 12.

4. Braude P, Carter B, Short R, Vilches-Moraga A, Verduri A, Pearce L, et al. The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19. *Int J Cardiol Heart Vasc*. 2020 Dec;31:100660.
5. Nunes JPL. Mortality and use of angiotensin-converting enzyme inhibitors in COVID 19 disease: a systematic review. *Porto Biomed J*. 2020 Nov-Dec;5(6):e085.
6. Xu J, Teng Y, Shang L, Gu X, Fan G, Chen Y, et al. The Effect of Prior ACEI/ARB Treatment on COVID-19 Susceptibility and Outcome: A Systematic Review and Meta-Analysis. *Clin Infect Dis*. 2020 Oct 20.
7. Ssentongo AE, Ssentongo P, Heilbrunn ES, Lekoubou A, Du P, Liao D, et al. Renin-angiotensin-aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis. *Open Heart*. 2020 Nov;7(2).
8. Li CK, Xu Z, Ho J, Lakhani I, Liu YZ, Bazoukis G, et al. Association of NPAC score with survival after acute myocardial infarction. *Atherosclerosis*. 2020 May;301:30-6.
9. Ju C, Lai RWC, Li KHC, Hung JKF, Lai JCL, Ho J, et al. Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users. *Rheumatology (Oxford)*. 2019 Dec 24.
10. Lau WCY, Cheung CL, Man KKC, Chan EW, Sing CW, Lip GYH, et al. Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation. *Ann Intern Med*. 2020 May 19.

11. Lau WC, Chan EW, Cheung CL, Sing CW, Man KK, Lip GY, et al. Association Between Dabigatran vs Warfarin and Risk of Osteoporotic Fractures Among Patients With Nonvalvular Atrial Fibrillation. JAMA. 2017 Mar 21;317(11):1151-8.
12. Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, et al. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circ Res. 2020 Jun 5;126(12):1671-81.
13. Li X, Guan B, Su T, Liu W, Chen M, Bin Waleed K, et al. Impact of cardiovascular disease and cardiac injury on in-hospital mortality in patients with COVID-19: a systematic review and meta-analysis. Heart. 2020 Aug;106(15):1142-7.
14. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Mar 27.
15. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020 Mar 25.
16. Wang Y, Roevers L, Tse G, Liu T. 2019-Novel Coronavirus-Related Acute Cardiac Injury Cannot Be Ignored. Curr Atheroscler Rep. 2020 May 7;22(3):14.
17. Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. Journal of Intensive Care. 2020 2020/07/10;8(1):49.

18. Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: Abnormal liver function tests. *J Hepatol*. 2020 Sep;73(3):566-74.
19. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020 Feb 15;395(10223):497-506.
20. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost*. 2020 Apr;18(4):844-7.

Table 1. Demographic, epidemiological, clinical characteristics and laboratory details of patients who were tested positive for COVID-19 in Hong Kong up to and including 28th July 2020. Patients were stratified by mortality status with latest available death information on 5th August 2020. COVID-19 = coronavirus disease 2019; APTT = Activated partial thromboplastin time; IQR = Interquartile range; * for $p \leq 0.05$, ** for $p \leq 0.01$, *** for $p \leq 0.001$

Characteristics	All COVID-19 patients (n=2774) Median (IQR) or count (%)	Death (n=42) Median (IQR) or count (%)	Alive (n=2732) Median (IQR) or count (%)	P value
Demographics				
Age, year,[IQR] max	43.54[28.61-60.00] 97.51	82.59[76.51,89.54] 95.59	42.885[28.24,59.47] 97.51	0.0031**
Sex				
Male	1369 (49.35%)	26 (61.90%)	1343 (49.16%)	<0.0001***
Female	1405 (50.65%)	16 (38.10%)	1389 (50.84%)	<0.0001***
Comorbidities				
Cardiovascular	196 (7.07%)	20 (47.62%)	176 (6.44%)	<0.0001***
Respiratory	2145 (77.33%)	36 (85.71%)	2109 (77.20%)	0.0122*
Kidney	133 (4.79%)	15 (35.71%)	118 (4.32%)	<0.0001***
Endocrine	29 (1.05%)	1 (2.38%)	28 (1.02%)	0.0013**
Diabetes	294 (10.60%)	18 (42.86%)	276 (10.10%)	<0.0001***
Hypertension	413 (14.89%)	24 (57.14%)	389 (14.24%)	<0.0001***
Gastrointestinal	2127 (76.68%)	32 (76.19%)	2095 (76.68%)	0.212
Drugs				
ACEI/ARB (baseline)	279 (10.06%)	16 (38.10%)	263 (9.63%)	<0.0001***
Steroids	143(5.16%)	6(14.29%)	137(5.01%)	<0.0001***
Lopinavir/Ritonavir (Kaletra)	29(1.05%)	4(9.52%)	25(0.92%)	0.355
Ribavirin	519(18.71%)	2(4.76%)	517(18.92%)	<0.0001***

Interferon beta	317(11.43%)	3(7.14%)	314(11.49%)	<0.0001***
Hydroxychloroquine	38(1.37%)	4(9.52%)	34(1.24%)	0.0126*
Calcium channel blockers	436(15.72%)	26(61.90%)	410(15.01%)	0.0233*
Beta blockers	182(6.56%)	12(28.57%)	170(6.22%)	0.0015**
Diuretics for heart failure	13(0.47%)	2(4.76%)	11(0.40%)	0.0016**
Diuretics for hypertension	8(0.29%)	1(2.38%)	7(0.26%)	0.0031**
Nitrates	25(0.90%)	1(2.38%)	24(0.88%)	0.0121*
Other Antihypertensive drugs	20(0.72%)	4(9.52%)	16(0.59%)	0.1351
Complete blood counts				
MCV, fL	86.4(82.5-90.0); n=1609	90.1(86.7-94.4); n=35	86.4(82.4-89.9); n=1574	0.0023**
Basophil, x10 ⁹ /L	0.01(0.0-0.03); n=2373	0.02(0.004-0.04); n=37	0.01(0.0-0.03); n=2336	0.116
Eosinophil, x10 ⁹ /L	0.1(0.01-0.17); n=2501	0.01(0.0-0.1); n=41	0.1(0.01-0.17); n=2460	0.0921
Lymphocyte, x10 ⁹ /L	1.6(1.2-2.1); n=2511	1.06(0.7-1.61); n=41	1.6(1.2-2.1); n=2470	<0.0001***
Metamyelocyte, x10 ⁹ /L	0.17(0.09-0.645); n=4	0.07(0.07-0.07); n=1	0.23(0.11-1.06); n=3	<0.0001***
Monocyte, x10 ⁹ /L	0.5(0.38-0.61); n=2511	0.6(0.43-0.7); n=41	0.5(0.38-0.61); n=2470	0.0422*
Neutrophil, x10 ⁹ /L	3.4(2.53-4.5); n=2511	6.69(4.5-11.61); n=41	3.37(2.5-4.47); n=2470	<0.0001***
WBC, x10 ⁹ /L	5.8(4.7-7.285); n=2589	7.87(6.48-12.16); n=41	5.79(4.7-7.2); n=2548	0.0321*
MCH, g/dL	33.8(33.0-34.5); n=2589	33.6(32.2-34.1); n=41	33.8(33.0-34.5); n=2548	0.0621
Myelocyte, x10 ⁹ /L	0.29(0.11-0.4); n=11	0.175(0.175-0.175); n=2	0.35(0.12-0.48); n=9	<0.0001***
Platelet, x10 ⁹ /L	237.0(180.0-298.0); n=2589	197.0(138.0-256.0); n=41	234.0(175.0-297.0); n=2548	<0.0001***
Reticulocyte, x10 ⁹ /L	44.15(27.85-58.15); n=20	42.8(42.8-42.8); n=2	45.0(26.5-63.2); n=18	<0.0001***
RBC, x10 ¹² /L	4.61(4.235-5.02); n=2589	3.97(3.23-4.38); n=41	4.62(4.25-5.02); n=2548	0.0721

Biochemical tests

Sodium, mmol/L	139.0(137.0-140.2); n=2591	137.2(133.2-144.155); n=41	139.0(137.0-140.1); n=2550	0.318
Potassium, mmol/L	3.8(2.6-3.78); n=2590	4.4(3.87-4.79); n=41	4.01(4.275-3.9); n=2549	0.217
Urea, mmol/L	4.0(3.14-5.0); n=2590	12.5(7.25-21.61); n=41	3.9(3.1-4.93); n=2549	<0.0001***
Creatinine, umol/L	68.0(57.0-82.0); n=2591	137.0(82.5-196.8); n=41	68.0(57.0-81.0); n=2550	<0.0001***
Albumin, g/L	40.0(35.3-43.8); n=2588	25.0(20.05-30.3); n=41	40.0(35.1-43.8); n=2547	0.4323
Protein, g/L	73.1(69.0-77.0); n=2323	66.1(60.8-72.0); n=31	73.4(69.6-77.0); n=2292	<0.0001***
Urate, mmol/L	0.3038(0.246-0.4041); n=111	0.32(0.292-0.62); n=3	0.3019(0.243-0.4019); n=108	0.3622
Alkaline Phosphatase, U/L	64.4(54.0-80.0); n=2587	84.0(68.0-117.0); n=41	64.0(54.0-79.0); n=2546	<0.0001***
Aspartate Transaminase, U/L	26.0(20.0-39.0); n=870	92.5(23.0-225.0); n=18	26.0(20.0-38.0); n=852	<0.0001***
Alanine Transaminase, U/L	24.0(16.0-39.0); n=2091	47.5(25.9-78.0); n=34	23.0(16.0-38.0); n=2057	<0.0001***
Bilirubin, µmol/L	8.0(5.8-12.0); n=2587	10.1(6.65-29.65); n=41	8.0(5.7-12.0); n=2546	<0.0001***
Cardiac function tests and clotting				
D-dimer, ng/mL	290.0(190.0-585.0); n=252	3278.59(3279.0-3279.0); n=1	290.0(190.0-580.0); n=251	<0.0001***
High sensitive troponin-I, ng/L	3.0(1.2-6.19); n=499	22.9(13.0-37.0); n=9	3.0(1.2-5.58); n=490	<0.0001***
Lactate dehydrogenase, U/L	175.0(150.0-201.0); n=1003	364.0(306.0-623.0); n=11	174.0(149.0-200.0); n=992	<0.0001***
Prothrombin time, sec	11.9(11.4-12.5); n=367	13.7(13.45-15.1); n=3	11.9(11.4-12.5); n=364	<0.0001***
APTT, sec	30.55(27.4-34.45); n=518	31.9(30.2-33.6); n=5	30.5(27.4-34.5); n=513	0.1309
Diabetes mellitus tests				
HbA1c, g/dL	13.4(12.4-14.5); n=2589	11.6(9.2-13.0); n=41	13.4(12.4-14.5); n=2548	<0.0001* **
Glucose, mmol/L	4.4(3.9-4.24); n=2038	7.9(6.01-8.9); n=37	8.8(3.2-7.6); n=2001	0.0035**
Cholesterol, mmol/L	2.1 (6.5-3.4); n=391	2.0(1.2-3.5); n=15	0.6(0.04-2.8); n=376	<0.0001* **

Triglycerides, mmol/L	1.3(0.9-1.9); n=404	1.4(1.0-1.7); n=16	1.3(0.9-1.9); n=388	0.051*
-----------------------	---------------------	--------------------	---------------------	--------

Table 2. Univariate Cox regression to predict mortality after COVID-19 presentation (n=2774)

Variable	Hazard ratio (95% CI)	Z value	P value
Sex	1.612[0.8605,3.019]	1.491	0.136
Age	1.132[1.104,1.161]	9.771	<0.0001***
Comorbidities			
Cardiovascular	13.25[7.181,24.44]	8.269	<0.0001***
Respiratory	1.723[0.7249,4.097]	1.232	0.218
Kidney	10.95[5.744,20.89]	7.267	<0.0001***
Endocrine	2.423[0.3331,17.63]	0.874	0.382
Diabetes mellitus	6.81[3.675,12.62]	6.096	<0.0001***
Hypertension	7.498[4.046,13.89]	6.402	<0.0001***
Gastrointestinal	0.9448[0.4632,1.927]	-0.156	0.876
Drugs			
ACEI/ARB (baseline)	5.87[3.13,11]	5.53	<0.0001***
Steroids	1.21[0.46,2.14]	2.005	0.0996
Lopinavir/Ritonavir (Kaletra)	11.64[4.15,32.67]	4.663	<0.0001***
Ribavirin	0.22[0.054,0.919]	-2.077	0.0378*
Interferon beta	0.613[0.1892,1.986]	-0.816	0.415
Hydroxychloroquine	1.04[0.45,2.11]	-0.006	0.0995
Calcium channel blockers	2.601[1.592,3.11]	6.721	0.0036**
Beta blockers	3.113[2.119,4.98]	5.274	0.0065**
Diuretics for heart failure	12.17[2.938,50.4]	3.446	0.0006***
Diuretics for hypertension	9.218[1.267,67.06]	2.194	0.0282*
Nitrates	2.773[0.3812,20.17]	1.007	0.3145
Other Antihypertensive drugs	6.61[5.92,46.62]	5.338	0.0112*
Complete blood counts			
MCV, fL	1.109[1.047,1.174]	3.534	<0.0001***

Basophil, x10 ⁹ /L	95.95[1.414,641]	2.037	0.0417*
Eosinophil, x10 ⁹ /L	1.972[0.3964,9.809]	0.829	0.407
Lymphocyte, x10 ⁹ /L	0.31[0.173,0.549]	-3.997	<0.0001***
Metamyelocyte, x10 ⁹ /L	1.113[0.7615,2.145]	-0.004	0.034*
Monocyte, x10 ⁹ /L	6.308[2.838,14.02]	4.519	<0.0001***
Neutrophil, x10 ⁹ /L	1.273[1.227,1.321]	12.71	<0.0001***
White blood count, x10 ⁹ /L	1.053[1.034,1.073]	5.58	<0.0001***
MCH, g/dL	0.661[0.539,0.811]	-3.962	<0.0001***
Myelocyte, x10 ⁹ /L	1.21[0.15,2.9]	-0.925	0.0351*
Platelet, x10 ⁹ /L	0.9891[0.9843,0.9941]	-4.318	<0.0001***
Reticulocyte, x10 ⁹ /L	0.9915[0.9504,1.034]	-0.396	0.692
Red blood count, x10 ¹² /L	0.1905[0.1259,0.2883]	-7.847	<0.0001***
Biochemical tests			
Sodium, mmol/L	1.012[0.9188,1.114]	0.233	0.816
Potassium, mmol/L	4.508[3.357,6.053]	10.02	<0.0001***
Urea, mmol/L	1.169[1.145,1.193]	15.15	<0.0001***
Creatinine, umol/L	1.005[1.004,1.006]	9.95	<0.0001***
Albumin, g/L	0.81[0.79,0.84]	-12.78	<0.0001***
Protein, g/L	0.8757[0.8431,0.9096]	-6.85	<0.0001***
Urate, mmol/L	151.4[0.03189,718363]	1.162	0.245
Alkaline Phosphatase, U/L	1.003[1.002,1.004]	4.727	<0.0001***
Aspartate Transaminase, U/L	1.002[1.001,1.002]	7.48	<0.0001***
Alanine Transaminase, U/L	1.013[1.01,1.016]	7.338	<0.0001***
Bilirubin, μmol/L	1.00[0.9999,1.001]	9.114	<0.0001***
Cardiac function tests and clotting			
D-dimer, ng/mL	1.00[0.9994,1.001]	1.669	0.0951.
High sensitive troponin-I, ng/L	1.005[1.004,1.006]	-0.097	0.923

Lactate dehydrogenase, U/L	1.079[0.8284,1.406]	7.777	<0.0001***
Prothrombin time, sec	1.41[1.116,1.78]	2.885	0.00391**
APTT, sec	1.035[0.8662,1.236]	0.377	0.706
Diabetes mellitus and lipid tests			
HbA1c, g/dL	0.5701[0.493,0.6593]	-7.579	<0.0001***
Glucose, mmol/L	1.164[1.103,1.229]	5.528	<0.0001***
Cholesterol, mmol/L	0.6611[0.4159,1.051]	-1.749	0.0802.
Triglycerides, mmol/L	0.9896[0.6185,1.583]	-0.044	0.965

Table 3. Multivariate Cox regression to predict mortality after COVID-19 presentation with significant univariate predictors as input (n=2774)

Variable	Hazard ratio (95% CI)	Z value	P value
Demographics			
Age	1.13[1.09, 1.20]	4.37	<0.0001***
Comorbidities			
Cardiovascular	1.12[0.47, 2.66]	1.28	<0.0001***
Kidney	1.25[0.42, 2.88]	2.14	0.0032**
Diabetes mellitus	1.81[0.77, 4.36]	2.22	0.0412*
Hypertension	0.84[0.36, 1.99]	-0.41	0.856
Drugs			
ACEI/ARB (baseline)	1.24[0.33, 2.78]	1.16	<0.0001***
Lopinavir/Ritonavir (Kaletra)	83.96[0.76, 103.11]	3.68	<0.0001***
Antihypertensive drugs	1.76[1.31, 9.21]	-0.28	0.322
Diuretics for heart failure	16.12[2.13, 121.21]	28.95	<0.0001***
Complete blood counts			
MCV, fL	1.03[0.95, 1.06]	0.72	0.1801
Monocyte, x10 ⁹ /L	0.70[0.14, 3.40]	-0.47	0.3411
Neutrophil, x10 ⁹ /L	1.10[1.01, 1.22]	2.13	0.0037**
White blood count, x10 ⁹ /L	1.03[0.90, 1.15]	0.16	0.2633
Biochemical tests			
Potassium, mmol/L	1.53[0.50, 4.68]	0.75	0.1734
Urea, mmol/L	1.15[1.07, 1.22]	3.72	0.0002***
Creatinine, umol/L	0.32[0.01, 1.19]	0.34	0.0166*
Albumin, g/L	0.84[0.73, 0.94]	-2.83	0.0041**
Protein, g/L	1.02[0.99, 1.11]	1.08	0.2563
Alkaline Phosphatase, U/L	1.03[0.99, 1.02]	1.53	0.0325*
Aspartate Transaminase, U/L	1.00[1.01, 0.99]	-0.10	0.0011**

Alanine Transaminase, U/L	1.00[1.00, 0.97]	1.42	0.213
Bilirubin, µmol/L	0.86[0.75, 1.03]	-1.62	0.4101
Lactate dehydrogenase, U/L	0.99[0.44, 1.58]	11.20	0.315
Diabetes mellitus tests			
Glucose, mmol/L	1.06[0.97, 1.16]	1.52	0.0037**